Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs
Key Highlights
- ➤Nociscan matched discography in up to 87% of 55 lumbar discs
- ➤Nociscan cost approximately £2,040 versus roughly £2,775 for discography
- ➤Nociscan avoided discography-associated pain flare-ups and two missed workdays
- ➤Study authors said MRS may eventually replace provocative lumbar discography
- ➤Aclarion reported Nociscan demonstrates a 97% surgical success rate when positive discs are treated
Expert Statements
John Sutcliffe, Consultant spinal neurosurgeon and lead clinician at the London Spine Clinic
“After more than three decades performing discography, I've seen firsthand how much this invasive procedure asks of patients, and how it may not always give us the answer”
John Sutcliffe, Consultant spinal neurosurgeon and lead clinician at the London Spine Clinic
“In our own clinic, we found that Nociscan tracked closely with what we saw on discography, at a lower cost, no added pain and no added risk to the patient. That's a meaningful step toward giving surgeons a reliable, noninvasive tool for identifying which disc is actually causing a patient's pain.”
Ryan Bond, Chief Strategy Officer of Aclarion
“Discography has been the default test for diagnosing painful discs for more than half a century, even though it is invasive, subjective, and its own reliability has been called into question in the literature”
Ryan Bond, Chief Strategy Officer of Aclarion
“Nociscan is designed to be a more patient-friendly test with more consistent and more objective results than a test that relies on a patient’s subjective response to pain. An agreement rate of up to 87% with an imperfect reference standard is a strong signal and exactly the kind of independent, real-world evidence that builds the case for physician adoption and payor support for Nociscan.”
* Study conducted at London Spine Clinic found Nociscan's noninvasive scan successfully identified painful discs, agreeing with discography, the invasive gold standard, in up to 87% of cases * Nociscan also spared patients the needles, added cost, and recovery time that is often associated with discography * Authors conclude Nociscan “may, in time, replace provocative lumbar discography” in appropriately selected patients * Bolsters the case for physician adoption and payor support for Nociscan BROOMFIELD, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the publication of a new, independent, peer-reviewed study, “MR Spectroscopy in the Diagnosis of Lumbar Discogenic Pain” in the European Spine Journal (ESJ). The study adds real-world validation to a growing body of clinical evidence supporting Nociscan.
Get started
Create a free account to read the full story.